See more : Chia Ta World Co., Ltd. (2033.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Knight Therapeutics Inc. (KHTRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Knight Therapeutics Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Prospect Resources Limited (PSC.AX) Income Statement Analysis – Financial Results
- SITE Centers Corp. (SITC) Income Statement Analysis – Financial Results
- Dazhong Transportation (Group) Co., Ltd. (600611.SS) Income Statement Analysis – Financial Results
- Awilco Drilling PLC (AWLCF) Income Statement Analysis – Financial Results
- Lumina Gold Corp. (LMGDF) Income Statement Analysis – Financial Results
Knight Therapeutics Inc. (KHTRF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.gud-knight.com
About Knight Therapeutics Inc.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 328.20M | 293.56M | 243.48M | 199.52M | 47.46M | 12.50M | 8.63M | 5.94M | 1.04M | 365.32K | 0.00 |
| Cost of Revenue | 175.55M | 155.50M | 128.07M | 117.83M | 20.54M | 2.31M | 1.59M | 1.55M | 428.00K | 0.00 | 0.00 |
| Gross Profit | 152.65M | 138.06M | 115.41M | 81.69M | 26.92M | 10.20M | 7.05M | 4.39M | 609.00K | 365.32K | 0.00 |
| Gross Profit Ratio | 46.51% | 47.03% | 47.40% | 40.94% | 56.72% | 81.56% | 81.64% | 73.91% | 58.73% | 100.00% | 0.00% |
| Research & Development | 17.55M | 14.76M | 12.69M | 11.73M | 3.91M | 1.99M | 2.75M | 1.96M | 2.71M | 1.03M | 0.00 |
| General & Administrative | 37.41M | 40.15M | 37.16M | 38.85M | 24.46M | 8.47M | 8.20M | 9.30M | 9.09M | 4.28M | 0.00 |
| Selling & Marketing | 46.28M | 48.47M | 37.22M | 35.59M | 7.79M | 3.59M | 3.38M | 532.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 83.69M | 88.62M | 74.38M | 74.43M | 32.25M | 12.06M | 11.58M | 9.83M | 9.09M | 4.28M | 0.00 |
| Other Expenses | 54.30M | 51.74M | 41.18M | 25.54M | 3.41M | 1.98M | 1.53M | 3.89M | 2.86M | 435.39K | 0.00 |
| Operating Expenses | 155.54M | 155.12M | 128.24M | 111.69M | 39.58M | 15.98M | 15.96M | 12.23M | 11.92M | 5.40M | 0.00 |
| Cost & Expenses | 331.09M | 310.62M | 256.31M | 229.52M | 60.12M | 18.28M | 17.54M | 13.78M | 12.35M | 5.40M | 0.00 |
| Interest Income | 12.58M | 10.63M | 7.38M | 14.32M | 23.54M | 20.93M | 26.30M | 24.41M | 18.63M | 3.90M | 0.00 |
| Interest Expense | 12.49M | 6.60M | 3.62M | 3.40M | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 23.54K | 0.00 |
| Depreciation & Amortization | 50.40M | 62.62M | 47.92M | 32.08M | 4.27M | 1.93M | 1.63M | 437.00K | 124.00K | 85.19K | 0.00 |
| EBITDA | 40.90M | 25.26M | 42.59M | 28.64M | 27.42M | -3.85M | -7.28M | -7.40M | -11.18M | -4.95M | 0.00 |
| EBITDA Ratio | 12.46% | 20.51% | 17.49% | 14.35% | 38.47% | -125.04% | -100.78% | -128.06% | 1,094.41% | -167.35% | 0.00% |
| Operating Income | -2.89M | -2.40M | -5.32M | -3.44M | 13.99M | -17.56M | -10.33M | -8.04M | 11.23M | -696.57K | 0.00 |
| Operating Income Ratio | -0.88% | -0.82% | -2.19% | -1.72% | 29.47% | -140.50% | -119.64% | -135.42% | 1,082.45% | -190.67% | 0.00% |
| Total Other Income/Expenses | -19.10M | -2.92M | 19.52M | 62.74M | 39.67M | 35.25M | 30.11M | 31.31M | 48.20M | 136.09M | 0.00 |
| Income Before Tax | -21.99M | -43.96M | 6.69M | 32.09M | 22.78M | 29.46M | 21.20M | 23.47M | 37.02M | 131.05M | 0.00 |
| Income Before Tax Ratio | -6.70% | -14.97% | 2.75% | 16.08% | 48.00% | 235.71% | 245.53% | 395.17% | 3,569.53% | 35,873.36% | 0.00% |
| Income Tax Expense | -5.15M | -14.07M | -8.99M | 325.00K | 4.75M | 5.39M | 3.96M | 4.91M | 2.85M | 5.19M | 0.00 |
| Net Income | -16.84M | -29.89M | 15.68M | 31.76M | 14.52M | 24.08M | 17.24M | 18.56M | 34.17M | 125.86M | 0.00 |
| Net Income Ratio | -5.13% | -10.18% | 6.44% | 15.92% | 30.59% | 192.63% | 199.72% | 312.46% | 3,294.79% | 34,451.40% | 0.00% |
| EPS | -0.16 | -0.26 | 0.13 | 0.24 | 0.10 | 0.17 | 0.12 | 0.15 | 0.36 | 2.20 | 0.00 |
| EPS Diluted | -0.16 | -0.26 | 0.13 | 0.24 | 0.10 | 0.17 | 0.12 | 0.15 | 0.35 | 2.20 | 0.00 |
| Weighted Avg Shares Out | 107.47M | 114.89M | 124.48M | 131.78M | 139.76M | 142.83M | 142.76M | 120.72M | 96.19M | 57.25M | 0.00 |
| Weighted Avg Shares Out (Dil) | 107.47M | 114.89M | 124.52M | 131.99M | 140.14M | 143.28M | 143.42M | 121.26M | 96.53M | 57.30M | 0.00 |
Knight Therapeutics - A Marshmallow Test of Patience
Knight Therapeutics Inc. (KHTRF) CEO Samira Sakhia on Q4 2021 Results - Earnings Call Transcript
Knight Therapeutics Inc. (KHTRF) CEO Samira Sakhia on Q3 2021 Results - Earnings Call Transcript
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
Knight Therapeutics Inc.'s (KHTRF) CEO Jonathan Ross Goodman on Q2 2021 Results - Earnings Call Transcript
Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q1 2021 Results - Earnings Call Transcript
Knight Therapeutics Inc. announces voting results from the Annual Meeting
Knight Therapeutics to Acquire Regional Rights to Exelon®
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports